Symbiotec Pharmalab LimitedPharmaceuticals & HealthcareSYMBIOTEC
Q1 FY27 concall · earnings callSymbiotec Pharmalab Limited
Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated revenue Q1 FY27 | ₹218 Cr | growth of 7% YoY | |
| API revenue Q1 FY27 | ₹215 Cr | growth of 6% YoY | |
| API EBITDA Q1 FY27 | ₹66 Cr | +9% YoY growth | |
| Consolidated EBITDA Q1 FY27 | ₹45 Cr | — | |
| Net profit Q1 FY27 | ₹14 Cr | — | |
| API gross margin Q1 FY27 | 60% plus | — | |
| Net debt as on 30th June | ₹398 Cr | — |
TL;DR
- Consolidated revenue was INR218 crores with growth of 7% year-on-year, largely from API revenues at INR215 crores with growth of 6% year-on-year driven by volume.
- API gross margins were 60% plus and API EBITDA was INR66 crores with 9% year-on-year growth, while consolidated EBITDA was INR45 crores and net profit about INR14 crores after INR23 crores opex and INR11 crores depreciation drag from new businesses.
- More than 90% of current fiscal revenues estimated from API business supported by 60 corticosteroid and steroidal hormones APIs, 44 US DMFs, 25 CEPs and over 200 customers across more than 40 countries.
- Biotech CDMO has a 5 year take-or-pay insulin drug substance contract, a 10-year take-or-pay alternate protein agreement and a 10-year take-or-pay term sheet, on a 400 kiloliter base with a 600 KL Phase 1 expansion planned.
- Complex injectables dual-chamber vial platform has first molecule ANDA filed and second filing scheduled for quarter four, with a US term sheet signed in August 2026 and definitive agreement expected in early Q3 FY27.
Said on the call
“In an industry where the regulatory trust is the ultimate currency, I consider this track record as one of the most valuable assets alongside our technology and manufacturing scale.”
From the Q&A
| Topic | What management said |
|---|---|
| Biotech CDMO capacity and revenue potential | Existing 400 kL fermentation capacity largely booked under Phase 0; Phase 1 expansion of 600 KL planned over 15 to 18 months with construction starting Q3, with visibility for 4 times bigger capacity from existing customers; each Phase 0 contract described as multi-million dollars opportunity but specific revenue contours not disclosed due to confidentiality. |
| API growth and margin sustainability | API business described as sticky due to backward integration and make versus buy flexibility, with focus on regulated markets and product and geography mix; management expects gross margins around 60% and EBITDA margins close to 30% with only small movements from logistics or solvent costs. |
| Complex injectables pipeline | First DCV molecule ANDA filed in September 2026 and second filing scheduled for quarter four; five to six additional products developed and moving to validation, but near-term constraint seen as capacity requiring a second line. |
| New business opex and milestones | INR23 crores quarterly operating expense drag and INR11 crores depreciation from new businesses expected to continue for next two to three quarters; H2 milestone revenues expected to set off full-year opex drag; prior year CDMO and injectable milestone revenue was roughly about INR33 crores in fourth quarter with nil in Q1 FY27. |
| Capex and utilization | API gross block close to INR640 crores delivering roughly INR800 crores - INR900 crores revenue at 70%-80% utilization; new businesses capex cumulatively more than INR1,000 crores with future capex of INR200 crores to INR250 crores each year. |
| Profit guidance and steady-state margins | Guidance of 20% revenue and 25% EBITDA growth is on consol basis; PAT growth will be lower due to depreciation drag while cash PAT growth is upwards of 25%; steady-state industry trend for complex CDMO and injectables cited as higher than 70% gross margins and higher than 35% EBITDA margins. |
Guidance
- Targeting 20% and 25% growth for this current fiscal year in revenues and EBITDA respectively, plus-minus 5% due to global operating environmental uncertainties
- New business revenues expected to commence in the next 6 to 12 months
- H2 expected to be very strong on milestone cash flows with some small revenues from biotech CDMO services in quarter four
- Continue to invest INR200 crores to INR250 crores each year for the next two to three years funded by internal accruals and partners' capital
- API gross margins expected around 60% and EBITDA margins close to 30%
- R&D investment of 3% to 4% of sales expected to continue, probably with a slight increase to about 5% in the future
Source
Summary written from the transcript filed by Symbiotec Pharmalab Limited for the call held on 22 Sept 2026; published 28 Sept 2026, 18:45 IST.
More Q1 FY27 concalls ·How verification works ·Report an error